Abbott Laboratories (NYSE: ABT) director receives 2,286-share restricted stock unit award

Rhea-AI Filing Summary

ABBOTT LABORATORIES director Michael F. Roman received an equity award covering 2,286 common shares. The Form 4 shows this as a grant or award acquisition at a stated price of $0.00 per share, bringing his directly held stake to 10,764 common shares after the transaction.

The footnote explains this is a restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program. The units will convert one-for-one into Abbott common shares upon the earlier of his separation from service, death, or a change in control as defined in the program.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Roman Michael F

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common shares without par value	2,286	$0.00	--

Holdings After Transaction: Common shares without par value — 10,764 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU award size: 2,286 shares Award price per share: $0.00 per share Post-transaction holdings: 10,764 shares +2 more

5 metrics

RSU award size 2,286 shares Restricted stock unit award covering Abbott common shares

Award price per share $0.00 per share Stated transaction price for the grant/award acquisition

Post-transaction holdings 10,764 shares Abbott common shares held directly after the award

Transaction date April 24, 2026 Date of the grant/award acquisition reported on Form 4

Transaction code A Classified as a grant, award, or other acquisition

Key Terms

Restricted stock unit award, Abbott Laboratories 2026 Incentive Stock Program, change in control, grant, award, or other acquisition

4 terms

Restricted stock unit award financial

"Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

Abbott Laboratories 2026 Incentive Stock Program financial

"award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program")"

change in control financial

"death, or the occurrence of a change in control (as defined in the Program)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

grant, award, or other acquisition financial

"transaction code description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roman Michael F

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	04/24/2026		A		2,286(1)	A	$0	10,764	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

	/s/ Michael F. Roman by Jessica H. Paik, Attorney-in-Fact	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ABBOTT LABORATORIES (ABT) report for Michael F. Roman?

ABBOTT LABORATORIES reported that director Michael F. Roman received an equity award covering 2,286 common shares. The Form 4 classifies this as a grant or award acquisition, not an open-market purchase or sale, reflecting compensation rather than a trading decision.

How many ABBOTT LABORATORIES (ABT) shares does Michael F. Roman hold after this Form 4?

After the reported grant, Michael F. Roman holds 10,764 ABBOTT LABORATORIES common shares directly. This figure, disclosed in the Form 4, represents his direct ownership immediately following the restricted stock unit award transaction on April 24, 2026.

What type of award did ABBOTT LABORATORIES (ABT) grant to director Michael F. Roman?

ABBOTT LABORATORIES granted Michael F. Roman a restricted stock unit award under its 2026 Incentive Stock Program. The award will be settled in Abbott common shares on a one-to-one basis upon specific events defined in the program rather than being immediately delivered.

When will Michael F. Roman’s ABBOTT LABORATORIES (ABT) restricted stock units be paid out?

The restricted stock units will be paid out in ABBOTT LABORATORIES common shares on the earlier of his separation from service, death, or a change in control. These triggering events are defined in the company’s 2026 Incentive Stock Program governing the award terms.

Did Michael F. Roman buy or sell ABBOTT LABORATORIES (ABT) shares in the market?

The Form 4 does not show a market buy or sell; it records a grant or award acquisition coded “A.” This reflects a compensation-related restricted stock unit award, with a stated price of $0.00 per share, rather than an open-market transaction by the director.

What program governs the ABBOTT LABORATORIES (ABT) restricted stock unit award to Michael F. Roman?

The award is governed by the Abbott Laboratories 2026 Incentive Stock Program. According to the footnote, this program defines the change in control terms and the events—separation from service, death, or such change in control—that trigger share delivery for the restricted stock units.